BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18060083)

  • 1. Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series.
    Checchi F; Piola P; Ayikoru H; Thomas F; Legros D; Priotto G
    PLoS Negl Trop Dis; 2007 Nov; 1(2):e64. PubMed ID: 18060083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
    Priotto G; Kasparian S; Mutombo W; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Baudin E; Buard V; Kazadi-Kyanza S; Ilunga M; Mutangala W; Pohlig G; Schmid C; Karunakara U; Torreele E; Kande V
    Lancet; 2009 Jul; 374(9683):56-64. PubMed ID: 19559476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo.
    Priotto G; Kasparian S; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Karunakara U
    Clin Infect Dis; 2007 Dec; 45(11):1435-42. PubMed ID: 17990225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda.
    Kansiime F; Adibaku S; Wamboga C; Idi F; Kato CD; Yamuah L; Vaillant M; Kioy D; Olliaro P; Matovu E
    Parasit Vectors; 2018 Feb; 11(1):105. PubMed ID: 29471865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness.
    Schmid C; Kuemmerle A; Blum J; Ghabri S; Kande V; Mutombo W; Ilunga M; Lumpungu I; Mutanda S; Nganzobo P; Tete D; Mubwa N; Kisala M; Blesson S; Mordt OV
    PLoS Negl Trop Dis; 2012; 6(11):e1920. PubMed ID: 23209861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.
    Mesu VKBK; Kalonji WM; Bardonneau C; Mordt OV; Blesson S; Simon F; Delhomme S; Bernhard S; Kuziena W; Lubaki JF; Vuvu SL; Ngima PN; Mbembo HM; Ilunga M; Bonama AK; Heradi JA; Solomo JLL; Mandula G; Badibabi LK; Dama FR; Lukula PK; Tete DN; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
    Lancet; 2018 Jan; 391(10116):144-154. PubMed ID: 29113731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study.
    Kuemmerle A; Schmid C; Bernhard S; Kande V; Mutombo W; Ilunga M; Lumpungu I; Mutanda S; Nganzobo P; Tete DN; Kisala M; Burri C; Blesson S; Valverde Mordt O
    PLoS Negl Trop Dis; 2021 Nov; 15(11):e0009903. PubMed ID: 34748572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo.
    Kuemmerle A; Schmid C; Kande V; Mutombo W; Ilunga M; Lumpungu I; Mutanda S; Nganzobo P; Ngolo D; Kisala M; Valverde Mordt O
    PLoS Negl Trop Dis; 2020 Jan; 14(1):e0008028. PubMed ID: 31986140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo.
    Alirol E; Schrumpf D; Amici Heradi J; Riedel A; de Patoul C; Quere M; Chappuis F
    Clin Infect Dis; 2013 Jan; 56(2):195-203. PubMed ID: 23074318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go.
    Chappuis F
    Clin Infect Dis; 2007 Dec; 45(11):1443-5. PubMed ID: 17990226
    [No Abstract]   [Full Text] [Related]  

  • 11. Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy.
    Amilon C; Boberg M; Tarning J; Äbelö A; Ashton M; Jansson-Löfmark R
    AAPS J; 2022 Mar; 24(3):48. PubMed ID: 35338410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in sleeping sickness therapy.
    Van Nieuwenhove S
    Ann Soc Belg Med Trop; 1992; 72 Suppl 1():39-51. PubMed ID: 1417168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo.
    Kazumba LM; Kaka JT; Ngoyi DM; Tshala-Katumbay D
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006504. PubMed ID: 29897919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NECT trial: more than a small victory over sleeping sickness.
    Opigo J; Woodrow C
    Lancet; 2009 Jul; 374(9683):7-9. PubMed ID: 19559477
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemotherapy for second-stage human African trypanosomiasis.
    Lutje V; Seixas J; Kennedy A
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD006201. PubMed ID: 23807762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial.
    Betu Kumeso VK; Kalonji WM; Rembry S; Valverde Mordt O; Ngolo Tete D; Prêtre A; Delhomme S; Ilunga Wa Kyhi M; Camara M; Catusse J; Schneitter S; Nusbaumer M; Mwamba Miaka E; Mahenzi Mbembo H; Makaya Mayawula J; Layba Camara M; Akwaso Massa F; Kaninda Badibabi L; Kasongo Bonama A; Kavunga Lukula P; Mutanda Kalonji S; Mariero Philemon P; Mokilifi Nganyonyi R; Embana Mankiara H; Asuka Akongo Nguba A; Kobo Muanza V; Mulenge Nasandhel E; Fifi Nzeza Bambuwu A; Scherrer B; Strub-Wourgaft N; Tarral A
    Lancet Infect Dis; 2023 Apr; 23(4):463-470. PubMed ID: 36460027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for second-stage Human African trypanosomiasis.
    Lutje V; Seixas J; Kennedy A
    Cochrane Database Syst Rev; 2010 Aug; (8):CD006201. PubMed ID: 20687080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment of human African trypanosomiasis.
    Pépin J; Milord F
    Adv Parasitol; 1994; 33():1-47. PubMed ID: 8122565
    [No Abstract]   [Full Text] [Related]  

  • 19. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire.
    Pépin J; Milord F; Meurice F; Ethier L; Loko L; Mpia B
    Trans R Soc Trop Med Hyg; 1992; 86(3):254-6. PubMed ID: 1412646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness.
    Yun O; Priotto G; Tong J; Flevaud L; Chappuis F
    PLoS Negl Trop Dis; 2010 May; 4(5):e720. PubMed ID: 20520803
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.